A new kind of pharmaceutical company delivering asset centricity at scale.

About Us

We represent a new kind of pharmaceutical company with a deconstructed R&D environment that prioritizes data driven decision making led by subject matter experts. Centessa companies are advancing a portfolio of high conviction programs with strong biological validation.

Our asset-centric model offers a unique R&D logic that has been applied by single asset companies to improve productivity. This operating model has minimal centralized infrastructure, reduced hierarchy, and exclusive focus on data driven capital allocation. Our teams are uniquely incentivized to expeditiously interrogate key scientific hypotheses. We believe the asset-centric model can lead to improved success rates for programs with greater speed and modest costs.

10 Companies.
173 Issued Patents.
Centessa Pharmaceuticals

  • Established 2013

    Roman Fleck, Ph.D.
    Patrick Gunning, Ph.D.

  • Established 2014

    Trevor Baglin, Ph.D.
    James Huntington, Ph.D.

  • Established 2014

    Donald Drakeman, J.D., Ph.D.
    Steve Holmes, Ph.D.

  • Established 2015

    Wei Li, Ph.D.
    Nick Morrell, M.D.
    Paul Upton, Ph.D.

  • Established 2015

    Lorenzo Pellegrini, Ph.D.

  • Established 2015

    David Grainger, Ph.D.
    Jim Huntington, Ph.D.

  • Established 2017

    Jamie Coleman, Ph.D.
    Jonny Finlay, Ph.D.

  • Established 2019

    Mario Alberto Accardi, Ph.D.
    Francesco De Rubertis, Ph.D.

  • Established 2019

    Johannes Heuckmann, Ph.D.
    Jonas Lategahn, Ph.D.
    Daniel Rauh, Ph.D.
    Carsten Schultz-Fademrecht, Ph.D.
    Martin Sos, M.D.
    Roman Thomas, M.D.
    Lead-Discovery-Center GmbH

  • Established 2019

    Jean-Pierre Armand, M.D., Ph.D.
    Aurélien Marabelle, M.D., Ph.D.
    Jean-Pierre Sommadossi, Ph.D.

  • Established January 2021